KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

12 May 2022 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports First Quarter 2022 Financial Results

05 May 2022 08:00:03 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

09 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

31 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 Dec 2021 09:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

13 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

22 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

15 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

11 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

08 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

04 Nov 2021 09:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

04 Nov 2021 09:00:02 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

04 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

02 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

05 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

02 Aug 2021 09:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

22 Jun 2021 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

11 Jun 2021 08:00:00 By Nasdaq GlobeNewswire